XBI

Morgan Stanley calls certain high‑risk biotech stocks "moonshots" that could see big gains if upcoming clinical tests go well. The firm stresses that success depends on several key factors.

Incyte has recently outperformed the broader biotech sector, drawing positive analyst sentiment. The company is gaining momentum in the market.

VHT offers broad healthcare exposure with lower volatility, while XBI focuses on biotech and carries higher risk and reward. The choice depends on an investor’s preference for diversification versus concentrated biotech play.

The ALPS Medical Breakthroughs ETF is highlighted as a good entry point into late‑stage biotech after a pullback.

Cathie Wood’s ARKG has added Ionis, Beam, Veracyte and Scribe Therapeutics to its holdings. The article lists other biotech ETFs that also hold her recent picks.

Novo Nordisk will hold its 2026 Capital Markets Day in London on Monday. The event is part of the biotech week’s broader focus on upcoming readouts and events.

Oncology spending is projected to reach $441B by 2029, with growth slowing from generics. The article lists five cancer stocks that may be overlooked by Wall Street.

Large‑cap healthcare outperformed this week: XLV gained 1.4%, while XBI fell 1.4% and IBB declined 0.5%. The piece notes XBI lost momentum after a strong 2026 run.